NO331002B1 - Tioxantinderivater og farmasoytiske preparater med tioxantinderivater - Google Patents

Tioxantinderivater og farmasoytiske preparater med tioxantinderivater

Info

Publication number
NO331002B1
NO331002B1 NO20044998A NO20044998A NO331002B1 NO 331002 B1 NO331002 B1 NO 331002B1 NO 20044998 A NO20044998 A NO 20044998A NO 20044998 A NO20044998 A NO 20044998A NO 331002 B1 NO331002 B1 NO 331002B1
Authority
NO
Norway
Prior art keywords
thioxanthine derivatives
pharmaceutical preparations
thioxanthine
derivatives
prophylaxis
Prior art date
Application number
NO20044998A
Other languages
English (en)
Norwegian (no)
Other versions
NO20044998L (no
Inventor
Sverker Hanson
Gunnar Nordvall
Anna-Karin Tiden
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201193A external-priority patent/SE0201193D0/xx
Priority claimed from SE0202239A external-priority patent/SE0202239D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20044998L publication Critical patent/NO20044998L/no
Publication of NO331002B1 publication Critical patent/NO331002B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20044998A 2002-04-19 2004-11-17 Tioxantinderivater og farmasoytiske preparater med tioxantinderivater NO331002B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201193A SE0201193D0 (sv) 2002-04-19 2002-04-19 Novel use
SE0202239A SE0202239D0 (sv) 2002-07-17 2002-07-17 Novel use
PCT/SE2003/000617 WO2003089430A1 (en) 2002-04-19 2003-04-15 Thioxanthine derivatives as myeloperoxidase inhibitors

Publications (2)

Publication Number Publication Date
NO20044998L NO20044998L (no) 2005-01-18
NO331002B1 true NO331002B1 (no) 2011-09-05

Family

ID=29253791

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20044998A NO331002B1 (no) 2002-04-19 2004-11-17 Tioxantinderivater og farmasoytiske preparater med tioxantinderivater
NO20100939A NO20100939L (no) 2002-04-19 2010-06-28 Tioksantinderivater som myeloperoksidaseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100939A NO20100939L (no) 2002-04-19 2010-06-28 Tioksantinderivater som myeloperoksidaseinhibitorer

Country Status (22)

Country Link
US (2) US7425560B2 (ru)
EP (2) EP1499613B1 (ru)
JP (2) JP4649112B2 (ru)
KR (3) KR20110132635A (ru)
CN (1) CN100379737C (ru)
AR (1) AR039385A1 (ru)
AT (1) ATE529428T1 (ru)
AU (2) AU2003224548B2 (ru)
BR (1) BR0309012A (ru)
CA (2) CA2480452C (ru)
ES (1) ES2373224T3 (ru)
HK (2) HK1071568A1 (ru)
IL (1) IL164315A0 (ru)
IS (1) IS7509A (ru)
MX (1) MXPA04010055A (ru)
MY (1) MY157949A (ru)
NO (2) NO331002B1 (ru)
NZ (1) NZ535406A (ru)
PL (1) PL373197A1 (ru)
RU (2) RU2323219C2 (ru)
TW (1) TWI335918B (ru)
WO (1) WO2003089430A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
WO2007120097A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2007142577A1 (en) * 2006-06-05 2007-12-13 Astrazeneca Ab Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090053176A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
US20100081159A1 (en) * 2008-09-26 2010-04-01 Lebedeva Irina V Profiling reactive oxygen, nitrogen and halogen species
WO2010062787A1 (en) * 2008-11-03 2010-06-03 Washington University Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses therefor
WO2010068171A1 (en) * 2008-12-12 2010-06-17 Astrazeneca Ab A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one
US20120122948A1 (en) * 2009-05-27 2012-05-17 Universite Libre De Beuxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011133581A1 (en) 2010-04-19 2011-10-27 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US8765126B2 (en) * 2011-05-05 2014-07-01 Robert Sackstein Methods of treating complications and disorders associated with G-CSF administration
EA027324B1 (ru) 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas
EP3397640B1 (en) * 2015-12-29 2021-08-04 INSERM - Institut National de la Santé et de la Recherche Médicale Xanthine derivative inhibitors of bet proteins
WO2020021300A1 (en) 2018-07-24 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2021013942A1 (en) 2019-07-24 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms
US20240166642A1 (en) 2022-08-18 2024-05-23 Astrazeneca Ab Inhibitors of myeloperoxidase

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) * 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
SE7810947L (sv) 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4710503A (en) * 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
AU2948189A (en) 1987-12-31 1989-08-01 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
DK440989A (da) 1988-09-12 1990-03-13 Smithkline Beecham Corp Dopamin-beta-hydroxylase inhibitorer
JPH02160235A (ja) 1988-12-13 1990-06-20 Konica Corp ハロゲン化銀カラー写真画像の形成方法
WO1990012797A1 (en) 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5100906A (en) 1990-04-19 1992-03-31 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
EP0730588B1 (en) * 1993-11-26 1997-07-02 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
WO1996018400A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
AU4527896A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Aryl thioxanthines
US5756511A (en) * 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) * 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US5976823A (en) * 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
WO2000059449A2 (en) 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
EP1202628B1 (en) 1999-08-12 2004-10-13 Euro-Celtique S.A. Novel hypoxanthine and thiohypoxanthine compounds
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
FR2811989A1 (fr) 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
EP1305328A2 (en) 2000-07-21 2003-05-02 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2819723B1 (fr) * 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
IL158462A0 (en) 2001-05-08 2004-05-12 Astrazeneca Ab An assay for detecting inhibitors of the enzyme myeloperoxidase
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MXPA06004789A (es) 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
US7713982B2 (en) 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CA2480452A1 (en) 2003-10-30
TWI335918B (en) 2011-01-11
AU2010200345B2 (en) 2011-07-07
RU2004128389A (ru) 2005-06-27
CN1646531A (zh) 2005-07-27
AU2003224548B2 (en) 2010-01-21
CN100379737C (zh) 2008-04-09
US7425560B2 (en) 2008-09-16
NO20044998L (no) 2005-01-18
AU2003224548A1 (en) 2003-11-03
ES2373224T3 (es) 2012-02-01
KR20040101525A (ko) 2004-12-02
KR101064092B1 (ko) 2011-09-08
JP2010138190A (ja) 2010-06-24
US8236951B2 (en) 2012-08-07
AU2010200345A1 (en) 2010-02-18
US20080293748A1 (en) 2008-11-27
MXPA04010055A (es) 2004-12-13
WO2003089430A1 (en) 2003-10-30
KR20110132635A (ko) 2011-12-08
NZ535406A (en) 2006-08-31
MY157949A (en) 2016-08-30
RU2323219C2 (ru) 2008-04-27
NO20100939L (no) 2005-01-18
IS7509A (is) 2004-10-15
HK1071568A1 (en) 2005-07-22
EP1499613B1 (en) 2011-10-19
RU2007142328A (ru) 2009-05-27
AR039385A1 (es) 2005-02-16
CA2752132A1 (en) 2003-10-30
BR0309012A (pt) 2005-02-01
EP1499613A1 (en) 2005-01-26
EP2332541A1 (en) 2011-06-15
IL164315A0 (en) 2005-12-18
ATE529428T1 (de) 2011-11-15
JP2005526836A (ja) 2005-09-08
TW200404803A (en) 2004-04-01
PL373197A1 (en) 2005-08-22
KR20110036871A (ko) 2011-04-11
JP4649112B2 (ja) 2011-03-09
US20050234036A1 (en) 2005-10-20
CA2480452C (en) 2011-11-22
HK1114500A1 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
NO331002B1 (no) Tioxantinderivater og farmasoytiske preparater med tioxantinderivater
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
NO20051263L (no) Ny anvendelse av benzotiazolderivater
NO20024014D0 (no) Ny bruk av fenylheteroalkylaminderivater
SE0202462D0 (sv) Novel use
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
NO20062370L (no) Amidderivater
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20004624D0 (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
NO963506L (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
NO20044571L (no) Isokinolinderivater
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
NO20045051L (no) 2,5-disubstituerte 3-mercaptopentansyre
SE0402591D0 (sv) Novel use
NO20024013L (no) Ny anvendelse av fenylheteroalkylaminderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees